West Pharmaceutical Services stock
WSTNYSEWest Pharmaceutical Services, Inc., HealthcareISIN US9553061055
78Score 78 out of 100, Strong
Price and trend
82 / 100
Price history
+49% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 29% above it.
Since May 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 62).
The price is at its 52-week high. Largest decline in 20 years: 60% (December 2021 to April 2025).
Chart figures for advanced users
- SMA 50$377.33
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$319.59
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)62
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$230.95
- The lowest closing price of the last twelve months.
- Resistance$416.67
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- West Pharmaceutical Services, Inc. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $28.76B, is number 7 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.07B (up 6.3% year on year) and earnings of $493.7M (up 0.2%).
- For fiscal 2026, analysts expect on average revenue of $3.42B (up 11.2%) and adjusted earnings per share of $9.46 (up 29.8%).
Show more
- MEQIRI Score 78 out of 100 (Strong): rank 36 of 714 in Healthcare, median 53.
- The P/E is 45.8 (Medical (Instruments & Supplies) median 34.8, own median of recent years 45).
- Our model puts fair value at $309.19, with the price 34% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for over 39 years.Capital allocation 80
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 87
- More cash than debtCash $464.1M, financial debt $305M.Stability 87
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are momentum and fundamentals, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $237.84 and expensive above $441.71 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $304.62 (cash-flow model) and $313.76 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $281.42, at 7.8% it would be $351.06.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 12.6% on the twelve months before. Revenue has grown solidly since 2006, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 36%, operating 20%, net 16%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 11 Feb 2027in 91 days
- Last reported
- 29 Oct 2026EPS reported $2.66 (expected $2.20)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 5.4% since 15 Oct 2026.
- Earnings per share
- $9.46+5.4%
- Revenue
- $3.42B+1.3%
- Earnings per share
- $10.34+3.1%
- Revenue
- $3.62B+0.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +2.2%West Pharmaceutical raised its full year guidance again: revenue now 3.41 to 3.42 billion dollars versus a prior 3.345 to 3.38 billion, and adjusted EPS 9.38 to 9.48 dollars versus a prior 8.85 to 9.05 dollars.
“Given the strong third quarter, we now anticipate full year revenue to be in the range of $3.41 billion-$3.42 billion, up from a prior range of $3.345 billion-$3.38 billion. This revised guidance assumes full year 2026 organic sales growth of 11.3%-11.6%, up from a prior range of 10%-11%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $3.52M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Favorite Annette FSale
15 Sept 2026, Sr. VP & Chief HR Officer
- Shares
- 2,524
- Price
- $365.00
- Value
- $921,260
- Favorite Annette FSale
14 Sept 2026, Sr. VP & Chief HR Officer
- Shares
- 2,500
- Price
- $355.00
- Value
- $887,500
- Favorite Annette FSale
11 Sept 2026, Sr. VP & Chief HR Officer
- Shares
- 2,500
- Price
- $345.00
- Value
- $862,500
Show 1 more
- Favorite Annette FSale
8 Sept 2026, Sr. VP & Chief HR Officer
- Shares
- 2,500
- Price
- $340.81
- Value
- $852,025
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at West Pharmaceutical Services
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 78
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- Becton, DickinsonBDX $58.43B59
- HOYA7741.T $50.12B76
- MedlineMDLN $37.04B55
- ResMedRMD $33.55B84
- Sartorius Stedim BiotechDIM.PA $24.55B58
- Straumann HoldingSTMN.SW $20.49B78
- SartoriusSRT.DE $17.6B59
- ColoplastCOLO-B.CO $16.54B69
ETFs that hold West Pharmaceutical Services
Held by 119 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI USA Mid-Cap Equal Weight UCITS ETFQDVC | 0.44% | 0.20% | €268.74M |
| UBS Factor MSCI USA Quality Screened UCITS ETF USD disUBUT | 0.43% | 0.25% | €1.14B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.42% | 0.15% | €3.27B |
Show 5 more
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.42% | 0.12% | €1.34B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.41% | 0.15% | €592.11M |
| First Trust US Large Cap Core AlphaDEX UCITS ETFFTGU | 0.37% | 0.75% | €140.24M |
| Fidelity Global Quality Income UCITS ETF INC-USDFGEQ | 0.36% | 0.40% | €1.03B |
| Deka MSCI USA MC UCITS ETFEL41 | 0.34% | 0.30% | €51.58M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 10 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.